As the Omicron variant of SARS-CoV-2 continues its global rampage, vaccine makers are pouring resources into clinical trials of COVID-19 shots tailored to the highly transmissible variant. But a raft of early animal studies suggest that Omicron-specific boosters offer no advantage over a third dose of current vaccines1–4.
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
doi: https://doi.org/10.1038/d41586-022-00003-y
References
Gagne, M. et al. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2022.02.03.479037v1?s=08 (2022).
Ying, B. et al. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2022.02.07.479419v1 (2022).
Lee, I.-J. et al. Preprint at bioRixv https://www.biorxiv.org/content/10.1101/2022.01.31.478406v1 (2022).
Hawman, D. W. et al. Preprint at bioRxiv https://www.biorxiv.org/content/10.1101/2022.01.31.478520v1 (2022).
Related Articles
-
Omicron thwarts some of the world’s most-used COVID vaccines
-
Does the world need an Omicron vaccine? What researchers say
Will Omicron end the pandemic? Here’s what experts say
How well can Omicron evade immunity from COVID vaccines?
Subjects
Latest on:
Jobs
-
Locum Associate or Senior Editor, Nature Plants
Job Title: Locum Associate or Senior Editor, Nature Plants Location: Shanghai, New Delhi - hybrid working model Closing date: January 11th, 2026 ...
Shanghai, New Delhi - hybrid working model
Springer Nature Ltd
-
-
-
-